ECSP12011928A - Vacuna de adn contra el virus de la fiebre amarilla - Google Patents

Vacuna de adn contra el virus de la fiebre amarilla

Info

Publication number
ECSP12011928A
ECSP12011928A ECSP12011928A ECSP12011928A EC SP12011928 A ECSP12011928 A EC SP12011928A EC SP12011928 A ECSP12011928 A EC SP12011928A EC SP12011928 A ECSP12011928 A EC SP12011928A
Authority
EC
Ecuador
Prior art keywords
yfe
construct
yellow fever
vfa
exposure
Prior art date
Application number
Other languages
English (en)
Inventor
Ernesto Torres De Azevedo Marques
Rafael Dhalia
Filho Romulo Maciel
Original Assignee
Fundacion Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Oswaldo Cruz filed Critical Fundacion Oswaldo Cruz
Publication of ECSP12011928A publication Critical patent/ECSP12011928A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a vacunas de ADN que codifican para secuencias virales específicas. Las vacunas de ADN contra la fiebre amarilla, desarrolladas según la invención, se basan en la secuencia que codifica para la proteína de la envuelta de VFA (p/YFE). Además de la construcción de tipo natural p/YFE, la secuencia E también se fusionó con la secuencia que codifica para la proteína asociada a la membrana humana lisosómica (h-LAMP), generando la construcción (pL/YFE). Los resultados de la invención se consideran muy prometedores puesto que las dos construcciones pueden inducir una respuesta de células T contra los mismos epítopos inducidos por la vacuna 17DD, y la construcción pL/YFE también podía inducir anticuerpos neutralizantes a una concentración considerada satisfactoria. El vector pL/YFE también se inoculó en ratones para la exposición intracerebral posterior con VFA. Sorprendentemente, el 100% de los ratones inmunizados con pL/YFE sobrevivieron a la exposición.
ECSP12011928 2009-10-27 2012-05-28 Vacuna de adn contra el virus de la fiebre amarilla ECSP12011928A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0905645A BRPI0905645B8 (pt) 2009-10-27 2009-10-27 vacina de dna contra o vírus da febre amarela

Publications (1)

Publication Number Publication Date
ECSP12011928A true ECSP12011928A (es) 2013-01-31

Family

ID=43922652

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011928 ECSP12011928A (es) 2009-10-27 2012-05-28 Vacuna de adn contra el virus de la fiebre amarilla

Country Status (11)

Country Link
US (3) US9393296B2 (es)
EP (1) EP2495325B1 (es)
AU (1) AU2010312258B2 (es)
BR (1) BRPI0905645B8 (es)
CA (1) CA2778893C (es)
CL (1) CL2012001093A1 (es)
EC (1) ECSP12011928A (es)
ES (1) ES2605654T3 (es)
PE (1) PE20130341A1 (es)
WO (1) WO2011050431A2 (es)
ZA (1) ZA201203862B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US7064842B1 (en) * 1999-01-13 2006-06-20 Olympus Optical Co., Ltd. Optical displacement sensor and optical encoder
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US6357374B1 (en) * 2000-07-21 2002-03-19 Cortana Corporation Method and apparatus for increasing the effectiveness and efficiency of multiple boundary layer control techniques
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
EP1385538B1 (en) * 2001-04-05 2013-01-30 The Johns Hopkins University Chimeric Vaccines comprising the lumenal domain of LAMP-1 or LAMP-2
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
US8586055B2 (en) * 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols

Also Published As

Publication number Publication date
EP2495325A4 (en) 2013-06-05
BRPI0905645B1 (pt) 2020-04-28
WO2011050431A3 (pt) 2011-09-15
WO2011050431A2 (pt) 2011-05-05
US20200188503A9 (en) 2020-06-18
US20190015499A1 (en) 2019-01-17
US10124052B2 (en) 2018-11-13
CA2778893A1 (en) 2011-05-05
CL2012001093A1 (es) 2012-10-19
US9393296B2 (en) 2016-07-19
EP2495325A2 (en) 2012-09-05
US20120308603A1 (en) 2012-12-06
EP2495325A9 (en) 2013-03-20
AU2010312258B2 (en) 2017-06-08
US20160324953A1 (en) 2016-11-10
BRPI0905645B8 (pt) 2021-05-25
BRPI0905645A2 (pt) 2011-06-21
AU2010312258A1 (en) 2012-06-21
US10888612B2 (en) 2021-01-12
CA2778893C (en) 2019-11-26
ZA201203862B (en) 2013-01-30
PE20130341A1 (es) 2013-04-24
ES2605654T3 (es) 2017-03-15
EP2495325B1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
Krammer Novel universal influenza virus vaccine approaches
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
ECSP088599A (es) Virus quiméricos que presentan proteínas de superficie no nativas y usos de los mismos
CY1118003T1 (el) Αναπτυξη συστατικων εμβολιου ιου δαγκειου
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
CY1115282T1 (el) Ανθρωπινα αντισωματα εναντι του ιου ηπατιτιδας c (hcv) χρησεις αυτων
DK1968632T3 (da) Forbedret influenzavaccine
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
AR059648A1 (es) Antigenos vacunales quimericos contra el virus de la peste porcina clasica
BRPI0813313A8 (pt) Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
ATE547116T1 (de) Kombinationsimpfstoff
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
ECSP12011928A (es) Vacuna de adn contra el virus de la fiebre amarilla
MX338052B (es) Vectores de parapoxvirus que contienen el antigeno del virus de la rabia.
BR112022003474A2 (pt) Vacinas do vírus da hepatite b
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina
BR112019010933A2 (pt) construções de vetor viral para expressão de adjuvantes genéticos que ativam a via de sting